Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib in Advanced EGFRm+ NSCLC (Part D)
NCT04075396Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Oct 2019; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04075396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075396.